丁二磺酸腺苷蛋氨酸治疗乙型肝炎病毒性肝硬化合并胆汁淤积的预后效果分析

Prognostic Effect of Adenosylmethionine Butadisulfonate in the Treatment of Hepatitis B Viral Cirrhosis Complicated with Cholestasis

目的 探讨乙型肝炎病毒性(Hepatitis B Virus, HBV)肝硬化合并胆汁淤积患者采用丁二磺酸腺苷蛋氨酸(Adenylmethionine Succinate, SAMe)开展治疗的预后效果。方法 单纯随机选取2022年2月—2023年2月新沂人民医院消化内科收治的80例HBV肝硬化合并胆汁淤积确诊患者作为研究对象,采用奇偶数字法分为对照组和研究组,每组40例。对照组以常规方案开展用药,研究组以对照组用药为基础增加使用SAMe。对两组肝功能、胆汁代谢指标、预后疗效以及不良反应进行对比观察。结果 治疗后,研究组谷草转氨酶、总胆红素以及谷丙转氨酶水平均低于对照组,差异有统计学意义(P均<0.05)。研究组血清甘胆酸、总胆汁酸水平低于对照组,差异有统计学意义(P均<0.05)。研究组治疗总有效率为97.50%,高于对照组的80.00%,差异有统计学意义(χ^(2)=6.135,P<0.05)。但两组药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论针对HBV肝硬化同时合并有胆汁淤积的患者,于常规保肝用药为基础上增加使用SAMe可有效提升预后疗效,促进患者肝功能与肝汁代谢功能改善,且不会导致不良反应增加,安全有效。

Objective To explore the prognostic effect of treating patients with hepatitis B virus(HBV)cirrhosis complicated by cholestasis with adenylmethionine succinate(SAMe).Methods A total of 80 patients diagnosed with HBV cirrhosis combined with cholestasis admitted to the Gastroenterology Department of Xinyi People's Hospital from February 2022 to February 2023 were simply and randomly selected as the study objects.They were divided into control group and study group by odd-even number method,with 40 cases in each group.The control group was treated with the usual regimen,and the study group was treated with SAMe based on the control group.Liver function,bile metabolism indexes,prognostic efficacy and adverse reactions were compared between the two groups.Results After treatment,the levels of aspartate transaminase,total bilirubin and alanine transaminase in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The levels of glycholic acid and total bile acid in the study group were lower than those in the control group,and the differences were statistically significant(both P<0.05).The total effective rate of the study group was 97.50%,which was higher than that of the control group(80.00%),and the difference was statistically significant(χ^(2)=6.135,P<0.05).There was no statistically significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion For patients with HBV cirrhosis combined with cholestasis,the addition of SAMe on the basis of conventional liver protection drugs can effectively improve the prognosis,improve the liver function and liver juice metabolism of patients,and will not lead to increased adverse reactions,and is safe and effective.